What happened when researchers tested combinations in people?
These four studies measured short-term responses under controlled conditions. Two tested terpenes with THC; two tested CBD with THC. They found different results.
Use this comparison as a starting point. The sections below explain who took part, what was tested and the limits of each finding. These are selected examples, not a complete review.
| Combination tested | Participants | What researchers found |
|---|---|---|
| Limonene + THC · 2024 | 20 overall; 12 in the strongest combination condition | Some anxiety ratings were lower. Most other measured effects did not change. |
| Alpha-pinene + THC · 2025 | 19 | Adding alpha-pinene did not protect against the memory impairment measured in this trial. |
| Inhaled CBD + THC · 2023 | 46 | Adding CBD did not significantly change memory or the other short-term outcomes reported. |
| Oral CBD-rich extract + THC · 2023 | 18 completers | The CBD-rich combination increased THC exposure and impairment. |
Limonene: an anxiety finding with an important qualification
A 2024 laboratory study tested inhaled d-limonene and THC in healthy adults who used cannabis intermittently. Selected ratings of anxiety and paranoia fell in a combination condition compared with THC alone. Most other measured effects did not change in the same way.
The strongest combination was tested last, in only 12 of the 20 participants. Unlike the principal randomized conditions, its position in the study could have influenced the result. Replication matters.
This is evidence about a particular acute response. It does not establish that citrus-smelling cannabis treats anxiety or that limonene makes intoxication stronger. The researchers disclosed a related patent application and industry relationships; the study received NIDA funding.
Pinene: the memory claim did not hold up in this trial
A 2025 study asked whether alpha-pinene could reduce THC-related memory impairment. Nineteen adults completed randomized, double-blind laboratory sessions comparing the compounds alone, together and with placebo.
Adding alpha-pinene did not mitigate the measured memory impairment or significantly change the other reported acute effects. That result challenges a familiar claim about pinene-rich cannabis. It does not answer every possible question about pinene, other terpenes or longer-term exposure.
The sample was small and the setting controlled. The paper reports NIDA funding and consulting, industry and terpene-business relationships.
CBD and THC: the route and formulation matter
A trial involving 46 healthy, infrequent cannabis users compared inhaled preparations containing the same THC amount with different CBD additions. CBD did not significantly change the primary memory outcome or the other reported acute effects under those conditions. The study was funded by the UK Medical Research Council; some authors disclosed pharmaceutical honoraria.
A separate oral-extract trial, with 18 completers, found greater THC-related exposure and impairment in its CBD-rich combination condition than with the same amount of THC without that addition. But it tested only particular amounts, had no CBD-only arm, and included an enzyme-probe drug cocktail that could have contributed to the behavioral outcomes.
These experiments do not support a simple rule that CBD always softens THC. They also show why a result from one route should not automatically be transferred to another.
The oral study received NIH funding. Authors disclosed industry consulting or contract work and a pending patent outside the submitted work.
Does an interaction have to be helpful?
No. An interaction can change an unwanted outcome as well as a desired one. The oral-extract experiment illustrates that greater exposure can accompany greater impairment. Calling a combination an “entourage” does not make that result beneficial.
When reading a claim, look for the outcome being discussed. Less anxiety, less memory impairment, pain relief and a stronger subjective drug effect are different outcomes. An improvement in one does not establish improvement in the others.
Do terpenes affect your high?
Some specific combinations have produced measurable changes in human experiments, while others have not. The limonene and pinene studies illustrate why the answer needs a compound, a measured outcome and a limitation attached to it.
A terpene percentage on a label is not the same thing as a controlled experiment. These studies do not validate a general system for predicting an individual experience from a terpene chart.
Use the terpene chart to compare aromas, plant examples and evidence. Use the terpene-profile guide to understand what the reported measurements mean. Neither is an effects prescription.
Why laboratory findings need their own section
Experiments in cells can investigate a possible mechanism. They cannot directly measure how a person feels. In a 2020 study, tested terpenoids did not produce the proposed changes in cannabinoid-receptor signaling. That narrows a mechanistic explanation under the tested conditions; it does not rule out every possible interaction elsewhere in the body.
Even the term’s history needs context. The 1998 paper introducing an entourage effect investigated the body’s own cannabinoid 2-AG and related compounds. It was not a clinical demonstration that cannabis terpene mixtures offer superior benefits.
Five questions to ask about an entourage claim
A useful explanation should make those answers easy to find. Personal experiences can prompt good research questions; controlled comparisons help determine which explanations hold up.
- Which combination? Named compounds or a chemically described extract are more informative than “full spectrum.”
- Who or what was studied? People, animals and isolated cells answer different questions.
- Compared with what? A placebo comparison alone may not isolate the contribution of an added ingredient.
- What changed? Look for a named outcome, not just the word “better.”
- What remains uncertain? Sample size, study order, formulation, funding and replication all deserve attention.


